<DOC>
	<DOCNO>NCT01026519</DOCNO>
	<brief_summary>This single-dose , double-blind , placebo-controlled , parallel group safety , tolerability pharmacodynamic study subcutaneously ( SC ) administer REGN88 rheumatoid arthritis patient receive concomitant methotrexate . Four ( 4 ) parallel group 8 subject active rheumatoid arthritis dose SC .</brief_summary>
	<brief_title>A Safety Tolerability Study REGN88 ( SAR153191 ) Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>1 . Male female â‰¥18 year age 2 . Subjects must weigh &gt; 50 &lt; 100 kg 3 . Diagnosis Rheumatoid Arthritis ( RA ) define 1987 revised American College Rheumatology ( ACR ) criteria disease duration le 6 month ACR class IIII 1 . A history Listeriosis active tuberculosis ( TB ) 2 . Persistent chronic active recur infection require treatment antibiotic , antiviral , antifungal within 4 week prior Screening Visit 3 . History prior articular prosthetic joint infection 4 . History hypersensitivity reaction , localize injection site reaction ( ISR ) , biological molecule 5 . Significant concomitant illness , limited cardiac , renal , neurological , endocrinological , metabolic lymphatic disease would adversely affect subject 's participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>